Everence Capital Management’s Eli Lilly LLY Stock Holding History

Everence Capital Management’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.7M	Hold	21,410	–	–	1.2%	16
2025 Q4	$23M	Hold	21,410	–	–	1.36%	16
2025 Q3	$16.3M	Buy	21,410 +60	+0.3%	+$44.6K	0.98%	16
2025 Q2	$16.6M	Sell	21,350 -930	-4%	-$723K	1.07%	16
2025 Q1	$18.4M	Sell	22,280 -60	-0.3%	-$49.9K	1.25%	13
2024 Q4	$17.2M	Buy	22,340 +690	+3%	+$571K	1.12%	15
2024 Q3	$19.2M	Hold	21,650	–	–	1.21%	14
2024 Q2	$16.9K	Hold	21,650	–	–	1.17%	13
2024 Q1	$16.8K	Hold	21,650	–	–	1.11%	13
2023 Q4	$12.6M	Hold	21,650	–	–	0.9%	17
2023 Q3	$11.6K	Hold	21,650	–	–	0.9%	15
2023 Q2	$9.3M	Hold	21,650	–	–	0.76%	22
2023 Q1	$7.43K	Sell	21,650 -150	-0.7%	-$50.6K	0.61%	28
2022 Q4	$7.97K	Hold	21,800	–	–	0.69%	26
2022 Q3	$7.05M	Hold	21,800	–	–	0.65%	24
2022 Q2	$7.07M	Buy	21,800 +3,750	+21%	+$1.13M	0.63%	26
2022 Q1	$5.17M	Buy	18,050 +2,910	+19%	+$749K	0.4%	48
2021 Q4	$4.18M	Sell	15,140 -6,420	-30%	-$1.63M	0.31%	59
2021 Q3	$4.98M	Hold	21,560	–	–	0.41%	41
2021 Q2	$4.95M	Buy	21,560 +7,430	+53%	+$1.49M	0.41%	45
2021 Q1	$2.64M	Hold	14,130	–	–	0.24%	72
2020 Q4	$2.39M	Sell	14,130 -3,590	-20%	-$536K	0.23%	73
2020 Q3	$2.62M	Sell	17,720 -3,100	-15%	-$480K	0.29%	62
2020 Q2	$3.18M	Hold	20,820	–	–	0.38%	46
2020 Q1	$2.89M	Hold	20,820	–	–	0.41%	45
2019 Q4	$2.74M	Sell	20,820 -2,464	-11%	-$286K	0.41%	49
2019 Q3	$2.6M	Hold	23,284	–	–	0.42%	49
2019 Q2	$2.58M	Sell	23,284 -2,500	-10%	-$294K	0.43%	51
2019 Q1	$3.35M	Sell	25,784 -621	-2%	-$75.5K	0.58%	34
2018 Q4	$3.06M	Hold	26,405	–	–	0.71%	28
2018 Q3	$2.83M	Hold	26,405	–	–	0.56%	40
2018 Q2	$2.25M	Hold	26,405	–	–	0.48%	49
2018 Q1	$2.04M	Hold	26,405	–	–	0.45%	56
2017 Q4	$2.23M	Buy	26,405 +140	+0.5%	+$11.9K	0.49%	48
2017 Q3	$2.25M	Hold	26,265	–	–	0.51%	47
2017 Q2	$2.16M	Hold	26,265	–	–	0.53%	42
2017 Q1	$2.21M	Hold	26,265	–	–	0.58%	41
2016 Q4	$1.93M	Sell	26,265 -5,330	-17%	-$397K	0.56%	46
2016 Q3	$2.54M	Hold	31,595	–	–	0.75%	28
2016 Q2	$2.49M	Sell	31,595 -2,740	-8%	-$206K	0.76%	31
2016 Q1	$2.47M	Buy	34,335 +8,970	+35%	+$679K	0.77%	30
2015 Q4	$2.14M	Sell	25,365 -4,930	-16%	-$409K	0.69%	39
2015 Q3	$2.54M	Buy	30,295 +1,570	+5%	+$133K	0.87%	27
2015 Q2	$2.4M	Buy	28,725 +10,467	+57%	+$798K	0.78%	33
2015 Q1	$1.28M	Hold	18,258	–	–	0.43%	61
2014 Q4	$1.26M	Sell	18,258 -9,730	-35%	-$657K	0.43%	59
2014 Q3	$1.78M	Hold	27,988	–	–	0.65%	39
2014 Q2	$1.74M	Buy	27,988 +3,840	+16%	+$229K	0.65%	39
2014 Q1	$1.42M	Hold	24,148	–	–	0.56%	49
2013 Q4	$1.23M	Buy	24,148 +2,281	+10%	+$114K	0.5%	55
2013 Q3	$1.1M	Hold	21,867	–	–	0.47%	61
2013 Q2	$1.07M	Buy	+21,867	New	+$1.19M	0.49%	57

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Everence Capital Management's LLY Position: Q1 2026 in Review

Everence Capital Management held its Eli Lilly (LLY) position steady in Q1 2026 at 21,410 shares worth $19.7M. The position accounts for 1.2% of the portfolio, ranked #16.

Everence Capital Management first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $23M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Everence Capital Management held 21,410 shares of Eli Lilly worth $19.7M as of Q1 2026.
Everence Capital Management left its Eli Lilly share count unchanged in Q1 2026.
Eli Lilly made up 1.2% of Everence Capital Management's portfolio in Q1 2026, its #16 holding.
Everence Capital Management first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
Everence Capital Management's Eli Lilly position peaked at $23M in Q4 2025.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.